Resultats de la cerca - Khan Nedd
- Mostrar 1 - 5 resultats de 5
-
1
Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study per Ulla Feldt‐Rasmussen, Derralynn Hughes, Gere Sunder‐Plassmann, Suma P. Shankar, Khan Nedd, Iacopo Olivotto, Damara Ortiz, Toya Ohashi, Takashi Hamazaki, Nina Skuban, Julie Yu, Jay Barth, Kathy Nicholls
Publicat 2020Artigo -
2
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease per Laura E. Case, Carl Bjartmar, Claire Morgan, Robin Casey, Joel Charrow, John Clancy, Majed Dasouki, Stephanie DeArmey, Khan Nedd, Mary Nevins, Heidi Peters, Dawn Phillips, Zachary Spigelman, Cynthia J. Tifft, Priya S. Kishnani
Publicat 2014Artigo -
3
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALA... per Eric Wallace, Özlem Göker-Alpan, William R. Wilcox, Myrl Holida, John Bernat, Nicola Longo, Aleš Linhart, Derralynn Hughes, Robert J. Hopkin, Camilla Tøndel, Mirjam Langeveld, Pilar Giraldo, Antonio Pisani, Dominique P. Germain, Ankit Mehta, Patrick Deegan, Mária Judit Molnár, Damara Ortiz, Ana Jovanović, Michael Muriello, Bruce A. Barshop, Virginia Kimonis, Bojan Vujkovac, Albina Nowak, Tarekegn Geberhiwot, Ilkka Kantola, Jasmine Knoll, Stephen Waldek, Khan Nedd, Amel Karaa, Einat Brill‐Almon, Sari Alon, Raul Chertkoff, Rossana Rocco, Anat Sakov, David G. Warnock
Publicat 2023Artigo -
4
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat per Dominique P. Germain, Derralynn Hughes, Kathy Nicholls, Daniel G. Bichet, Roberto Giugliani, William R. Wilcox, Claudio Feliciani, Suma P. Shankar, Fatih Süheyl Ezgü, Hernan Amartino, Drago Bratkovic, Ulla Feldt‐Rasmussen, Khan Nedd, Usama Sharaf El Din, Charles Marques Lourenço, Maryam Banikazemi, Joel Charrow, Majed Dasouki, David N. Finegold, Pilar Giraldo, Özlem Göker-Alpan, Nicola Longo, C. Ronald Scott, Roser Torrá, Ahmad Tuffaha, Ana Jovanović, Stephen Waldek, Seymour Packman, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Elfrida R. Benjamin, Franklin K. Johnson, David J. Lockhart, Nina Skuban, Jeff Castelli, Jay Barth, Carrolee Barlow, Raphael Schiffmann
Publicat 2016Artigo -
5
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study per Derralynn Hughes, Kathy Nicholls, Suma P. Shankar, Gere Sunder‐Plassmann, David M. Koeller, Khan Nedd, Jerry Vockley, Takashi Hamazaki, Robin Lachmann, Toya Ohashi, Iacopo Olivotto, Norio Sakai, Patrick Deegan, David Dimmock, François Eyskens, Dominique P. Germain, Özlem Göker-Alpan, É. Hachulla, Ana Jovanović, Charles Marques Lourenço, Ichiei Narita, Mark Thomas, William R. Wilcox, Daniel G. Bichet, Raphael Schiffmann, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Franklin K. Johnson, Pol Boudes, Elfrida R. Benjamin, David J. Lockhart, Carrolee Barlow, Nina Skuban, Jeffrey P. Castelli, Jay Barth, Ulla Feldt‐Rasmussen
Publicat 2016Artigo
Eines de cerca:
Matèries relacionades
Disease
Internal medicine
Medicine
Fabry disease
Enzyme replacement therapy
Adverse effect
Renal function
Urology
Bioinformatics
Biology
Cardiology
Chaperone (clinical)
Clinical trial
Gastroenterology
Glycogen storage disease type II
Pathology
Pediatrics
Pharmacology
Randomized controlled trial
Regimen
Surgery